Inhibitors of lysine specific demethylase-1
AssigneeCelgene Quanticel Research, Inc.
InventorsYoung Chen, Toufike Kanouni, Jeffrey Alan Stafford, James Veal
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds as exemplified as follows, The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
Claims29
A compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein:
- A is C—R, wherein R is optionally substituted alkyl;
- W1 and W2 are independently chosen from N, C—H, or C—F;
- X is hydrogen, halogen, optionally substituted alkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, optionally substituted alkynyl, optionally substituted carbocyclylalkynyl, optionally substituted aryl, or optionally substituted heteroaryl;
- Y is optionally substituted alkyl, optionally substituted cycloalkylalkyl, heterocyclylalkyl or aralkyl;
- and
- Z is an optionally substituted group chosen from N-heterocyclyl, —O-heterocyclylalkyl, —N(H)-heterocyclylalkyl, or —N(Me)-heterocyclylalkyl;
- wherein if Z is an optionally substituted heterocyclylalkyl group selected from —O— heterocyclylalkyl, —N(H)-heterocyclylalkyl or —N(Me)-heterocyclylalkyl, then heterocyclylalkyl group has the formula —Rc-heterocyclyl, wherein Rc is an optionally substituted C1-C3 alkylene chain and the heterocyclyl is an optionally substituted nitrogen-containing 5-membered heterocyclyl.
Dependencies are inferred from the claim text.